We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance on Reporting Drug Impurities in ANDA Revised
FDA Guidance on Reporting Drug Impurities in ANDA Revised
February 4, 2005
The FDA has made significant revisions to a guidance that recommends what types of drug impurity data included with drug applications.